Benjamin Porter-Brown

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

Joachim Sieper, Benjamin Porter-Brown, Liz Thompson et al. · Annals of the Rheumatic Diseases · 2013 · 205 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab

Andrea Rubbert‐Roth, Anthony Sebba, Laura Brockwell et al. · RMD Open · 2016 · 60 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +9

Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources

Jeffrey R. Curtis, Susana Perez‐Gutthann, Samy Suissa et al. · Seminars in Arthritis and Rheumatism · 2014 · 51 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effects of tocilizumab on neutrophil function and kinetics

Laurence S. C. Lok, Neda Farahi, Jatinder K. Juss et al. · European Journal of Clinical Investigation · 2017 · 48 citations · Full text

Life Sciences, Immunology, Pharmacology +15

OP0166 Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial

J. Sieper, Benjamin Porter-Brown, Liz Thompson et al. · Annals of the Rheumatic Diseases · 2012 · 26 citations

Medicine, Immunology, Pharmacotherapy +13